Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

163.89
+0.70000.43%
Post-market: 165.001.11+0.68%17:30 EST
Volume:613.75K
Turnover:100.75M
Market Cap:8.38B
PE:-44.54
High:165.56
Open:163.13
Low:162.39
Close:163.19
52wk High:191.50
52wk Low:86.99
Shares:51.15M
Float Shares:41.87M
Volume Ratio:0.70
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6800
EPS(LYR):-3.6821
ROE:-252.11%
ROA:-16.81%
PB:94.95
PE(LYR):-44.51

Loading ...

Axsome Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jan 29

Axsome Therapeutics (AXSM) Valuation Check As Phase 3 AXS 14 Fibromyalgia Trial Gets Underway

Simply Wall St.
·
Jan 28

U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth

Reuters
·
Jan 28

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

GlobeNewswire
·
Jan 27

Axsome Therapeutics Chief Commercial Officer Ari Maizel Reports Disposal of Common Shares

Reuters
·
Jan 24

Axsome Therapeutics (AXSM) Is Up 7.4% After Advancing AXS-14 Into Phase 3 FORWARD Fibromyalgia Trial

Simply Wall St.
·
Jan 23

Axsome Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 21

Axsome Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Jan 21

RBC Raises Price Target on Axsome Therapeutics to $219 From $212, Keeps Outperform Rating

MT Newswires Live
·
Jan 21

Axsome Therapeutics price target raised to $219 from $212 at RBC Capital

TIPRANKS
·
Jan 21

Axsome Therapeutics Inc : RBC Raises Target Price to $219 From $212

THOMSON REUTERS
·
Jan 21

U.S. RESEARCH ROUNDUP-IBM, KLA, WEX

Reuters
·
Jan 21

Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 20

Reaffirming Axsome Therapeutics as a Buy on Robust Commercial Growth and Advancing Late‑Stage Pipeline, With a Raised $260 Price Target

TIPRANKS
·
Jan 20

Axsome Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 17

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
Jan 16

Axsome Therapeutics Launches Phase 3 FORWARD Trial of AXS-14 for Fibromyalgia

Reuters
·
Jan 15

Axsome Therapeutics Initiates Forward Phase 3 Trial of Axs-14 for the Management of Fibromyalgia

THOMSON REUTERS
·
Jan 15

Axsome Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jan 13

Axsome Therapeutics price target raised to $209 from $157 at Baird

TIPRANKS
·
Jan 13